St. Cloud Surgical Center is First ASC in U.S. to Utilize Xenex Germ-Zapping Robot to Disinfect Operating Rooms & Enhance Patient Safety more

4 cheap small cap stocks I’ve got my eye for Christmas more

Southern Biologics Network Established to Create Biologics Faster and Less Expensively more

Morningside Ministries at the Manor is the First Skilled Nursing Facility in Texas to Protect Residents with Xenex Germ-Zapping Robot more

RBA to cut rates in 2015: Still want to invest in term deposits? more

Can robots help stop the Ebola outbreak? more

Robots Help Fight Ebola more

South Florida Hospital Unveils Ebola-Zapping Robot more

Sonoma Valley Hospital uses robot to kill germs more

Robots go to war against Ebola more

New iTraumaCare CEO to pursue big growth more

UAB and SRI have plans to spinoff more success more

Launch of Galderma's new acne products more

iTraumaCare’s new CEO to help company secure new funding more

U.S. Air Force Hospital Langley Adds Xenex Ebola-Zapping Robot to Inventory more

Forthcoming Acne Treatment Made With Exclusive (And Sustainable) East Indian Sandalwood Oil more

Sonoma Valley Hospital Acquires Xenex Germ-Killing Robot to Enhance Patient Safety more

Robot fights germs at Sharp Chula Vista Medical Center more

Xenex updates protocols for germ-zapping robots in response to Ebola threat more

How do we get rid of the endotoxins? Birmingham's  has the solution more

Medical Device ® Positions New Leader for Next-Level Growth more

The Xenex robot at South Shore Hospital featured on an Xploration Earth more

Germ-zapping robot Gigi sets its sights on Ebola more

Morningside Ventures leads a Series B round for DNAtrix more

StemBioSys secures new research space at BioBridge Global more

Birmingham's Soluble Therapeutics acquires Seattle company Dilyx Biotechnology more

Company invents germ-zapping robot more

Xenex Congratulates Houston Cancer Hospital more

Australian grown Indian Sandalwood timber attracts lucrative Asian markets more

DNATRIX ANNOUNCES TREATMENT OF FIRST PATIENT WITH DNX-2401 more

Targeted Technology raises more than $40 million more

Reducing Healthcare Associated Infections (HAIs): Not All UV Light is the Same more

Bluegrass Vascular Technologies Names Dr. Gabriele Niederauer President And CEO more

Three Birmingham companies recognized in PwC report more

Former Kinetic Concepts Inc. CEO to lead StemBioSys more

International dermatology company Galderma confirmed more

AUSTRALIAN Sandalwood producer TFS Corporation will supply oil more

San Antonio luring biotech firms with venture capital more

Biotech firm secures nearly $5 million in funding, is relocating to San Antonio more

Birmingham is on the front lines of medical research: take a look at this incredible biotech startup more

Germ-Zapping Robots Fight C. diff and MRSA at Mercy Health Saint Mary's more

Milford hospital enlists robots in war against infections more

Xenex Testifies About UV Room Disinfection Technology Effectiveness to U.S. House of Representatives more

Western Pa. hospitals test robot using ultraviolet rays to kill bacteria more

Xenex Demonstrates UV Room Cleaning System’s Effectiveness in Reducing Hospital Acquired Infections more

TFS flags record full-year profit more

Sweet scented sandalwood flavour of month

Overseas demand has prompted Australian listed Sandalwood producer TFS Corporation to predict it will generate exports of $1 billion over the next decade.

"We use the whole tree," TFS chief executive Frank Wilson told AAP during a recent tour of the company's Kununurra operations.

"The crops we're planting today will harvest 20 times what we were planting 15 years ago."

Almost 10 years after listing on the Australian Securities Exchange, TFS has just produced its first harvest and is filling orders from a major international pharmaceutical company focused on skin products.

As well as pharmaceutical applications, TFS is also targeting fragrance and cosmetics companies in North America, China, India and Europe.

And it's hoping for increased investor interest later this year once a client releases treatments for acne and eczema products.

The Perth-based company, which has operations throughout Australia, believes it will have a 15 year jump on competitors who seek to begin planting trees.

One fully grown Indian Sandalwood tree can fetch around $7000, with the roots and trunk producing valuable oil, carving wood for the Chinese market and incense for religious purposes in India.

Survival rates were now much better than a few years ago and the trees were growing bigger and stronger, using a variety of host trees, Mr Wilson said.

Mr Wilson says the premium price for fine carving wood, which is highly prized for furniture in China, is around $160,000 per tonne.

"Tables and cabinets sell for $1 million in China," he said.

With prices like these, the incentive for thieves and black market traders is great.

Police in regional Western Australia have been kept busy in recent years, chasing criminals who have illegally harvested dozens of tonnes of Sandalwood in sophisticated operations.

And with one eye on the thefts, TFS is stepping up security at its Kununurra operations in north Western Australia.

"Security is becoming a bigger issue for us," Mr Wilson said.

"The risk is that organised crime gets involved at the forest point."

TFS has a total of 3.2 million trees on 8000 hectares of land in WA, Queensland and the Northern Territory and it's in the hunt for more land acquisitions after opening its Kununurra processing plant in September last year.

Mr Wilson concedes there has been a lot of trial and error involved in growing the trees, which he says require host trees to reach their full potential.

The company cultivates 600,000 seedling per year which need to cope with temperatures of 55 degrees as well as tropical storms and flooding.

Still, for Mr Wilson, a TFS director, former lawyer, professional AFL footballer and farmer's son, it hasn't been all plain sailing.

In November last year TFS' directors survived a board spill after more than a third of its shareholders voted against adopting the company's remuneration report for the second year due to the company's performance and corporate governance.

The company's share price has doubled since then, giving some of the dissident shareholders less ammunition ahead of this year's annual general meeting. back

House committee looks for new technology in Veterans Affairs hospitals more

FDA grants fast track status to drug DNX-2401 for recurrent Glioblastoma more

CEO shakeup at San Antonio biotech company StemBioSys more

First harvest to be completed in June more

BiO2 Medical Enrolls Subjects in the New U.S. FDA Early Feasibility Pilot Study for the Angel® Catheter more

San Antonio biotech firm readies skin treatment for distribution more

ViroXis Gets Approval To Initiate FDA Phase 2 Study For Molluscum Contagiosum more

Medical technologies conference announces speaker lineup more

Australian sandalwood sells for millions more

Sandalwood exports as good as gold more

Santalis Pharmaceuticals Signs Exclusive License Agreement with Global Pharmaceutical Company to Commercialize OTC Dermatology Products more

ViroXis Corporation Signs Exclusive License Agreement with Global Pharmaceutical Company to Commercialize an OTC Dermatology Product more

DNAtrix Awarded $10.8 Million Grant by the Cancer Prevention and Research Institute of Texas more

ViroXis Corporation Achieves Key Clinical Milestones more

There are growing concerns about the threat of an antibiotic crisis caused by the spread of drug-resistant superbugs. Those concerns could result in more